Arcellx

ACLXPhase 1

Arcellx is pioneering next-generation cell therapies for cancer patients, leveraging proprietary technologies to develop more effective and durable CAR-T cell treatments. The company's lead programs target hematologic malignancies with novel approaches designed to improve patient outcomes and overcome treatment resistance. As a publicly traded company, Arcellx is advancing multiple clinical programs while building a robust pipeline of innovative cellular immunotherapies.

Market Cap

$6.7B

Focus

Biotech

ACLX · Stock Price

USD 114.77+98.51 (+605.84%)

Historical price data

AI Company Overview

Technology Platform

Proprietary CAR-T cell engineering platform focused on developing next-generation cellular immunotherapies with enhanced functionality and durability for cancer treatment.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
SPRX002 + ARC-T Cells	Acute Myeloid Leukemia	Phase 1
anito-cel + Standard Lymphodepletion regimen	Muscular Diseases	Phase 1

Funding History

Total raised: $340M

IPO$140MUndisclosedJan 28, 2022

Series B$115MQuan CapitalMar 15, 2021

Series A$85MNovo HoldingsJan 15, 2020

Opportunities

Significant growth potential in the expanding CAR-T cell therapy market, with opportunities to address limitations of current treatments and expand into new indications including potential solid tumor applications.

Risk Factors

Clinical development risks inherent in cell therapy development, intense competition in the CAR-T space, manufacturing complexity and scalability challenges, and the need for continued capital to fund development programs.

Competitive Landscape

Operates in a highly competitive CAR-T cell therapy market alongside established players like Kite Pharma, Novartis, and Bristol Myers Squibb, with differentiation likely based on proprietary technology approaches and clinical profiles.

Publications

Patents

Pipeline